NCT03345433

Brief Summary

The purpose of this research is to determine if it is possible to perform group drumming as an intervention during HCT, to begin to understand how interactive group drumming during HCT treatment affects patients' well-being (good and bad) during the treatment course and in the first four weeks after completion of the drumming sessions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 20, 2017

Completed
26 days until next milestone

Study Start

First participant enrolled

November 15, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 17, 2017

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 25, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 4, 2019

Completed
Last Updated

May 14, 2020

Status Verified

December 1, 2019

Enrollment Period

1.9 years

First QC Date

October 20, 2017

Last Update Submit

May 11, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Rate of participation

    Defined as the number of subjects willing to participate in the interactive group drumming (IGD) divided by the number approached and asked to participate. These rates will be reported, along with the corresponding 95% confidence interval.

    Up to 1 week after hematopoietic cell transplant (HCT)

  • Rate of completion

    Defined as the ratio of (the number of individuals who successfully complete the study \[4 sessions of IGD (about 20 minutes \[min.\] each)\], with two pre-and post- surveys \[8 minutes total, and two questionnaires (10 minutes total) about 160 minutes total time\]) relative to the number of individuals who consent to the study (the number from the numerator of the first ratio \[participation\]). These rates will be reported, along with the corresponding 95% confidence interval.

    Up to 1 week after HCT

Secondary Outcomes (6)

  • Gather patient-reported data to suggest how participants respond to interactive group drumming (IGD)

    Baseline up to 4 weeks after completion of IGD

  • Determine optimum length of session

    Up to 4 weeks after completion of IGD

  • Gather patient-reported information to study whether the effect of interactive group drumming (IGD) on targeted variables is more pronounced in successive sessions

    Baseline up to 4 weeks after completion of IGD

  • Effect of support care provider (SCP) presence for each participant and among participants

    Up to 4 weeks after completion of IGD

  • Change in physiological response to interactive group drumming (IGD)

    Baseline up to 1 week after HCT

  • +1 more secondary outcomes

Study Arms (1)

interactive group drumming sessions

EXPERIMENTAL

Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.

Behavioral: interactive group drumming sessions

Interventions

interactive group drumming sessions

interactive group drumming sessions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • People who are at least 18 years old and are scheduled for HCT
  • Individuals must be able to understand and willing to sign a written informed consent form

You may not qualify if:

  • People who are too ill to participate, i.e., while they are in contact isolation or have low platelets (less than 20,000/mcl) will not participate until their condition has improved.
  • Patients receiving outpatient HCT except patients with multiple myeloma. Patients with multiple myeloma may participate in the study even though they tend to spend nights away from the hospital.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location

Study Officials

  • Richard McQuellon, PhD

    Wake Forest University Health Sciences

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Model Details: interactive group drumming sessions
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 20, 2017

First Posted

November 17, 2017

Study Start

November 15, 2017

Primary Completion

September 25, 2019

Study Completion

December 4, 2019

Last Updated

May 14, 2020

Record last verified: 2019-12

Locations